VasCir

VasCir is a medical technology company focused on improving vascular access outcomes for patients with end-stage renal disease (ESRD) undergoing hemodialysis. The company's primary mission is to address the high failure rates associated with arteriovenous fistulas (AVFs), which are the preferred method of vascular access but often fail to mature or succumb to stenosis. VasCir is developing a proprietary device designed to optimize the mechanical and biological environment of the fistula to promote successful maturation and long-term patency. Led by experienced leaders in vascular surgery and biotechnology, the company aims to reduce the clinical and economic burden of vascular access complications.